Skip to main content

52-Acre Development Looks to Capitalize on Houston's Growing Life Sciences Industry

Published Jun 16, 2020 by A.J. Mistretta

levit green.jpg

A rendering of Levit Green

A massive new mixed-use development planned near the Texas Medical Center is the latest in a series of projects that will expand Houston’s life sciences research and innovation infrastructure.  

Hines plans to redevelop a 52-acre site near the intersection of Texas 288 and Holcombe Blvd. in partnership with the Levit family which has owned the property for generations. Dubbed Levit Green, the project is slated to include a mix of office space, research facilities, retail, residential and green space. 

The developers hope to build on Houston’s growing life sciences sector centered around the TMC, the world’s largest medical campus with more than 60 different hospitals and institutions. Construction on the first phase of Levit Green is slated to start next year. 

“At 15.5%, Houston has one of the highest five-year growth rates in life sciences establishments in the United States,” said John Mooz, senior managing director at Hines. “Impressive advancements in therapeutics, science and innovation are driving demand for real estate. With multimodal connectivity and proximity to TMC, we believe Levit Green will create a new and needed destination for Houston’s rapidly growing life sciences cluster.”

Earlier this year, Texas A&M University announced plans to create Texas A&M Innovation Plaza, a $550 million mixed-use complex on the edge of the TMC. The 5-acre project being developed in phases through 2024 will include education space for the university’s dual-degree program in medicine and engineering, student housing and commercial space for clinical, research and office use. On the south end of TMC, work is slated to begin this year on TMC3, a 37-acre, 1.5 million-square-foot translational research campus that will include labs and research facilities as well as commercial and retail space and a hotel/conference center. Construction on the project is expected to be completed in 2022. 

The Houston Chronicle estimates that together these projects will bring roughly $2 billion in investment to the area around TMC. 

Houston is home to more than 1,700 life sciences companies and roughly 320,000 workers across the region are employed in healthcare and life sciences—more than the total employment of the energy sector. 

Learn more about Houston's life sciences industry

Related News

Life Sciences

Houston’s Biotech Ecosystem: The Ideal Launchpad for Life Sciences Startups

3/28/25
Launching a biotech startup is one of the most difficult undertakings in science and business. For Sarah Hein, founder and CEO of March Biosciences, choosing Houston made all the difference.  While most early-stage companies struggle to navigate the so-called "valleys of death" — the critical and often underfunded stages between research breakthroughs and real-world treatments — March Biosciences found the support it needed to move fast and scale its innovation. Hein credits Houston’s robust life sciences ecosystem for making that possible – saying Houston is one of the few places where you can go from the lab to commercialization.   “Houston has unique infrastructure and opportunities that made building March Bio here an obvious choice—the scientific and medical expertise of the largest medical center in the world, the local talent pool from that medical center, and then partnership opportunities,” Hein told the Greater Houston Partnership.  Want to learn more about Houston’s life sciences and biotech ecosystem, connect with the Partnership’s Global Life Sciences Sr. Director Verena Kallhoff.  From Research to a Life-Saving Therapy  March Bio was founded out of the Center for Cell and Gene Therapy (CAGT), a collaboration among Baylor College of Medicine (BCM), Houston Methodist and Texas Children’s Hospital. At the CAGT, March Bio worked with scientists to develop its lead therapy, MB-105, a CAR-T cell treatment targeting T-cell lymphoma and T-cell acute lymphoblastic leukemia, two aggressive cancers with limited treatment options.  CAR-T cell therapy involves collecting a patient’s own immune cells, engineering them to better recognize and attack cancer, and then reintroducing them into the body. Proximity to patients is essential for this personalized approach, and Houston’s concentration of clinical expertise makes it an ideal hub. As of mid-2024, the region hosted more than 2,200 active clinical trials, accounting for 11 percent of all trials in the U.S.  MB-105 showed a 44 percent patient response rate in Phase 1 trials at BCM. With that early success, March Bio turned to Houston’s ecosystem to accelerate its development.  Strategic Partnerships   In 2023, March Bio announced a strategic alliance with the CTMC, a joint effort between National Resilience and MD Anderson Cancer Center. CTMC provides biotech startups with comprehensive support, from development and manufacturing to regulatory guidance.   “Our close collaboration with MD Anderson Cancer Center provides access to leading regulatory expertise and one of the world's largest clinical trial programs, ensuring promising therapies reach patients faster,” Amy Hay, Chief Business Officer of CTMC, told the Partnership.  CTMC’s infrastructure enabled March Bio to grow without the financial burden of building its own facilities. “By taking on the heavy operational costs—housing the program in our 60,000 SF industrial-grade cGMP facility—CTMC enabled March to remain lean and focused on innovation,” she explained.   Fueling Growth Through Investment  Beyond research and partnerships, Houston offers the capital resources biotech companies need to grow, and March Biosciences has tapped into them at every stage of its journey.   The company secured early investment from the TMC Venture Fund and Portal Innovations, a venture capital firm that expanded to Houston in 2023 with the goal of supporting startups through funding, lab space and commercialization expertise.  “Portal’s investment in Houston is a mark of the growth and potential of the ecosystem,” said Hein. “March was their first biotech deal in Houston, and that early seed capital allowed us to get a lot of critical work done which set us up for our later financing success.”   March Bio’s momentum continued in 2024 with a $28.4 million Series A financing round, bringing its total amount raised to over $51 million.  Today, March Bio operates out of Portal’s labs at TMC Helix Park, where the company is currently conducting ongoing product development and early-stage discovery work.  State-level funding has been instrumental in fueling March Bio’s growth, with the Cancer Prevention and Research Institute of Texas (CPRIT) playing a significant role. March Bio was awarded a $13.4 million CPRIT grant to support its Phase 2 clinical trial. What sets CPRIT apart is that it is a state agency, established and funded by the State of Texas, making it one of the largest state-funded efforts against cancer. CPRIT has provided more than $3 billion in funding for cancer research and biotech innovation across Texas, contributing to a thriving life sciences ecosystem. With $6 billion dedicated to advancing cancer breakthroughs, CPRIT’s comprehensive approach supports the entire cancer care continuum while driving economic growth by attracting biotech companies and creating jobs. The company also received support from the Cancer Focus Fund, a MD Anderson–backed initiative that helps advance promising oncology therapies toward commercialization.  A Houston Success Story  Just four years after its founding in 2021, March Bio has advanced into Phase 2 trials and earned FDA orphan drug designation for MB-105. This designation is an important milestone that provides incentives such as tax credits and market exclusivity for rare disease treatments.  “Houston is home to the largest medical center in the world, with particular excellence in oncology, cardiovascular, and neurology research,” said Hein. “Patients come from all over the world to access the world class clinicians and novel clinical trials. Frankly, I think we simply have to keep doing the hard work of translating that leading research into the clinic, focusing on collaboration and growing our bench of talent, and the growth will follow.”  With its interconnected network of research institutions, capital resources, and strategic partners, Houston is proving to be a top destination for biotech companies. As the region continues investing in life sciences, more innovators like March Biosciences are expected to emerge, driving groundbreaking discoveries from concept to commercialization. 
Read More
Health Care

United Imaging Announces Major Expansion of U.S. Manufacturing Space

2/6/25
[PRESS RELEASE Provided by United Imaging] January 9, 2025 -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has signed on for additional production and office space in greater Houston. The new space in Pearland, Texas will more than triple the total size of the company's current manufacturing square footage that's now at their North American headquarters on Kirby Drive. It was only just over four years ago that the company opened that current production facility.    United Imaging has been steadily increasing U.S. production since then, with products in all four imaging modalities it currently sells achieving local production in Texas over the last four years. All critical spare parts are already stored in Houston and in stocking locations across the country.  "With the steadily spiking demand and manufacturing capacity also has come an increase in hiring" said Jeffrey M. Bundy, PhD, CEO of United Imaging Healthcare North America. Since 2021, U.S. headcount growth has averaged 60% annually.  The proximity to Houston's ports provides strategic opportunity the global company has been investing in for years, with increasing operations in South America and across the world. United imaging also announced recently its first product registrations in Canada. It has installations in 75+ countries worldwide since 2011, and earlier this summer announced its 30,000th unit installed globally, which was in the U.S.  At United Imaging, we develop and manufacture advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change. To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC. 
Read More

Related Events

Executive Partners